<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2021.111004</article-id><article-id pub-id-type="publisher-id">WJCR-40035</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20210100000_36372363.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  结直肠癌靶向药物治疗的应用与进展
  Application and Progress of Targeted Drug Therapy for Colorectal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>严</surname><given-names>双丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>荣生</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>剑华</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大理大学临床医学院，云南 大理</addr-line></aff><aff id="aff3"><addr-line>大理大学第一附属医院，云南 大理</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>24</fpage><lpage>31</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    在我国，结直肠癌发病率呈逐年增加趋势，靶向药物联合化疗已成为晚期结直肠癌治疗的趋势所在，近几年随着靶向药物治疗的应用，很大程度上延长了晚期结直肠癌患者的生存期。同时，由于对结直肠癌病因学、分子生物学、细胞学的不断升入研究及相关试验开展，新的靶向药物不断涌现。本文综述了结直肠癌靶向治疗的临床应用与研究进展。
    In China, the incidence rate of colorectal cancer is increasing year by year. Targeted drug combination chemotherapy has become the trend of treatment for advanced colorectal cancer. In recent years, with the application of targeted drug therapy, the survival time of patients with advanced colorectal cancer has been greatly extended. At the same time, with the development of the research on the etiology, molecular biology and cytology of colorectal cancer, new targeted drugs are emerging. This paper reviews the clinical application and research progress of targeted therapy for colorectal cancer. 
  
 
</p></abstract><kwd-group><kwd>结直肠癌，靶向治疗，血管内皮生长因子，表皮生长因子，临床应用，研究进展, Colorectal Cancer</kwd><kwd> Targeted Therapy</kwd><kwd> Vascular Endothelial Growth Factor</kwd><kwd> Epidermal Growth 
Factor</kwd><kwd> Clinical Application</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>在我国，结直肠癌发病率呈逐年增加趋势，靶向药物联合化疗已成为晚期结直肠癌治疗的趋势所在，近几年随着靶向药物治疗的应用，很大程度上延长了晚期结直肠癌患者的生存期。同时，由于对结直肠癌病因学、分子生物学、细胞学的不断升入研究及相关试验开展，新的靶向药物不断涌现。本文综述了结直肠癌靶向治疗的临床应用与研究进展。</p></sec><sec id="s2"><title>关键词</title><p>结直肠癌，靶向治疗，血管内皮生长因子，表皮生长因子，临床应用，研究进展</p></sec><sec id="s3"><title>Application and Progress of Targeted Drug Therapy for Colorectal Cancer</title><p>Shuangli Yan<sup>1</sup>, Rongsheng Zhang<sup>2</sup>, Jianhua Wang<sup>2</sup></p><p><sup>1</sup>College of Clinical Medicine, Dali University, Dali Yunnan</p><p><sup>2</sup>First Affiliated Hospital of Dali University, Dali Yunnan</p><p><img src="//html.hanspub.org/file/4-2150203x4_hanspub.png" /></p><p>Received: Dec. 27<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/4-2150203x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In China, the incidence rate of colorectal cancer is increasing year by year. Targeted drug combination chemotherapy has become the trend of treatment for advanced colorectal cancer. In recent years, with the application of targeted drug therapy, the survival time of patients with advanced colorectal cancer has been greatly extended. At the same time, with the development of the research on the etiology, molecular biology and cytology of colorectal cancer, new targeted drugs are emerging. This paper reviews the clinical application and research progress of targeted therapy for colorectal cancer.</p><p>Keywords:Colorectal Cancer, Targeted Therapy, Vascular Endothelial Growth Factor, Epidermal Growth Factor, Clinical Application, Research Progress</p><disp-formula id="hanspub.40035-formula19"><graphic xlink:href="//html.hanspub.org/file/4-2150203x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-2150203x7_hanspub.png" /> <img src="//html.hanspub.org/file/4-2150203x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>根据2018年全球癌症负担的现状报告，结直肠癌(Colorectal Cancer, CRC)发病率在恶性肿瘤排名全球第三，中国第四，死亡率却位列第二 [<xref ref-type="bibr" rid="hanspub.40035-ref1">1</xref>]。对于CRC的主要治疗方法还是以手术为主，以局部或全身的化疗和放疗为辅，然后再进行综合性的治疗。目前随着肿瘤分子生物学及精准医疗的不断发展，分子靶向治疗、个体化治疗已成为一种新型有效的治疗方法 [<xref ref-type="bibr" rid="hanspub.40035-ref2">2</xref>]，越来越多的癌症驱动基因被发现，针对相应靶点的靶向药物应用而生，本文就结直肠癌的靶向治疗的应用结合国际前沿研究结果综述如下。</p></sec><sec id="s6"><title>2. 结直肠癌分子靶点及相关药物</title><sec id="s6_1"><title>2.1. 以VEGF、VEGFR为靶点的靶向治疗</title><p>血管内皮生长因子(Vascular endothelial growth factor, VEGF)在启动和促进肿瘤血管生成中起着复杂的作用。VEGF家族由VEGF-A、VEGF-B、VEGF-C、VEGF-D和胎盘生长因子(PLGF1-4)组成。它们与肿瘤血管生成、维持血管通透性、趋化性、迁移、分化和存活有关。肿瘤周围的血管与肿瘤的生长有着密切的关系，在肿瘤血管生长的过程中血管内皮生长因子的细胞因子起着调控的作用，它通过和内皮细胞表面的受体进行结合，从而促进肿瘤新生血管的形成 [<xref ref-type="bibr" rid="hanspub.40035-ref3">3</xref>]。</p><sec id="s6_1_1"><title>2.1.1. 贝伐珠单抗</title><p>贝伐珠单抗(Bevacizumab)是一种重组人源化、人鼠嵌合抗VEGF的单克隆抗体。它是通过与血管内皮生长的因子相结合，从而达到拮抗血管内皮细胞的生理活性，从而包括影响血管的渗透性、增生以及内皮细胞迁移与存活，达到抑制肿瘤血管生成、生长以及转移的效果 [<xref ref-type="bibr" rid="hanspub.40035-ref4">4</xref>]。于2004年获得美国食品与药物管理局(FDA)的批准，是首个用于临床的VEGF相关的靶向药物。在我国于2010年被批准上市，在转移性结直肠癌、乳腺癌、肺癌、肾癌、多形性成胶质细胞瘤等广泛应用。国内外己经有很多的临床观察研究证实了贝伐珠单抗具有良好的临床安全性，发生严重不良事件的概率低，同时相关不良反应与细胞毒性药物并不重叠 [<xref ref-type="bibr" rid="hanspub.40035-ref5">5</xref>]。与单纯化疗相比，贝伐珠单抗与一线化疗药物联用可提高抗肿瘤效果，这可能是由于贝伐珠单抗可减小异常细胞内组织间隙的压力，从而加强了化疗药物在肿瘤内部的渗透作用 [<xref ref-type="bibr" rid="hanspub.40035-ref6">6</xref>]。</p><p>Hurwitz [<xref ref-type="bibr" rid="hanspub.40035-ref7">7</xref>] 等进行了一项回顾性分析，在813例先前未治疗的转移性结直肠癌患者随机分成两组，贝伐珠单抗联合化疗组(n = 402)和安慰组(n = 411)，通过贝伐珠单抗联合5-氟尿嘧啶(5-FU) + 亚叶酸钙 + 伊立替康及单纯化疗进行对比，结果显示，贝伐珠单抗组的总生存期(overall survival, OS)较单纯化疗组的OS相比显著延长(15.6个月对20.3个月)，延长了4.7个月，死亡危险比为0.66 (P &lt; 0.001)。而两组的无进展生存期(Progression-Free Survival, PFS)分别为10.6个月和 6.2个月，客观缓解率(Objective Response Rate, ORR)分别为44.8%和34.8%，差异有统计学意义，在以氟尿嘧啶为基础的联合化疗中加入贝伐单抗可在转移性结直肠癌患者的生存中获得临床意义上的改善。</p><p>Cohen [<xref ref-type="bibr" rid="hanspub.40035-ref8">8</xref>] 等进行了多中心随机对照试验，将829例患者分成3组：FOLFOX4 (奥沙利铂、5-氟尿嘧啶、亚叶酸钙)治疗组(292例)、FOLFOX4联合贝伐珠单抗治疗组(293例)和单独贝伐珠单抗治疗组(244例)。结果显示FOLFOX4联合贝伐珠单抗组的OS较单纯化疗组的OS相比明显延长，由6.2个月延长至10.6个月，而两组的PFS分别为4.5个月和7.5个月，客观反应率(ORR)明显提高(22.2% vs 8.6%)。2006年6月，FDA批准贝伐单抗与FOLFOX4联合应用于转移性结直肠癌的二线治疗。经过多次单中心、大样本临床研究，贝伐珠单抗联合化疗已成为转移性结直肠癌(Metastatic colorectal cancer, mCRC)一线、二线治疗的首选，在临床应用中疗效显著。</p></sec><sec id="s6_1_2"><title>2.1.2. 雷莫芦单抗</title><p>雷莫芦单抗(Ramucirumab)是作为VEGFR-2拮抗剂，重组IgG1单克隆抗体。它与VEGFR2的胞外区具有很强的特异性和亲和力，能阻止VEGFR2和所有VEGF配体形成二聚体，从而阻断VEGF和VEGFR2介导的信号传导和血管生成，通过此机制可抑制肿瘤新生血管的生成，阻断对肿瘤细胞的血液供应，从而导致肿瘤细胞的凋亡、崩解 [<xref ref-type="bibr" rid="hanspub.40035-ref9">9</xref>]。目前已被批准作为晚期胃癌或胃食管交界区腺癌(单一用药或与紫杉醇联合)、转移性结直肠癌中(联合FOLFIRI方案)、转移性非小细胞肺癌(联合多西紫杉醇治疗)的二线治疗 [<xref ref-type="bibr" rid="hanspub.40035-ref10">10</xref>]。</p><p>在一线奥沙利铂或氟尿嘧啶联合贝伐单抗化疗下，RAISE试验评估了在FOLFIRI进展后加入雷莫芦单抗的情况，对患者PFS和OS有显著改善 [<xref ref-type="bibr" rid="hanspub.40035-ref11">11</xref>]。根据RAISE临床试验的结果，2015年4月，FDA批准雷莫芦单抗与FOLFIRI联合使用，用于治疗转移性结直肠癌患者 [<xref ref-type="bibr" rid="hanspub.40035-ref11">11</xref>]。Garcia-Carbonero等 [<xref ref-type="bibr" rid="hanspub.40035-ref12">12</xref>] 通过纳入了48例患者进行II期临床试验，结果显示接受雷莫芦单抗联合化疗后中位PFS为11.5个月，疾病控制率为93.8%。最常见的3~4级不良事件包括中性粒细胞减少(3级：33.3%；4级：8.3%)、高血压(3级：16.7%)和神经病变(3级：12.5%)。由此可得出雷莫芦单抗可提高FOLFOX-6化疗的疗效，在转移性CRC中具有较高的安全性及耐受性。</p></sec><sec id="s6_1_3"><title>2.1.3. 阿柏西普</title><p>阿柏西普(Aflibercept)是由血管内皮生长因子受体(Vascular endothelial growth factor receptor, VEGFR)胞外结构域(即VEGFR1 Ig2区和VEGFR2 Ig3区)与人免疫球蛋白G1的Fc段相结合的一种重组融合蛋白，作用于靶点VEGF-A、VEGF-B和胎盘生长因子(placental growth factor, PLGF)抑制肿瘤血管的生成 [<xref ref-type="bibr" rid="hanspub.40035-ref13">13</xref>]。根据已有相关研究进展阿柏西普确实对多种实体瘤特别是mCRC有明确的抗肿瘤作用。</p><p>VELOUR试验 [<xref ref-type="bibr" rid="hanspub.40035-ref14">14</xref>] 得到了批准，对1226例mCRC患者随机分配为阿柏西普组(n = 612)和对照组(n, 614)，然后每2周进行FOLFIRI化疗。主要终点为OS，两年生存率分别为28.0%和18.7%。与单纯FOLFIRI化疗相比，阿柏西普组的患者OS延长(13.50个月对12.06个月)，PFS延长(6.90个月对4.67个月)。目前被FDA批准与二线FOLFIRI化疗联合使用，用于对OX的一线方案无效的mCRC患者 [<xref ref-type="bibr" rid="hanspub.40035-ref15">15</xref>]。现仍有一些临床试验在进行中，用来评估阿柏西普的有效性、安全性及耐受性。</p></sec></sec><sec id="s6_2"><title>2.2. 以EGFR为靶点的靶向治疗</title><p>表皮生长因子受体(Epithelial Growth Factor Recepto, EGFR)是EGFR受体酪氨酸激酶家族的成员之一，由胞外区(配体结合)、跨膜区和胞内区(含酪氨酸激酶结构域)构成 [<xref ref-type="bibr" rid="hanspub.40035-ref16">16</xref>]。当胞外区与配体结合时，胞内区酪氨酸激酶自磷酸化，激活下游信号通路，造成基因的突变与扩增，导致酪氨酸激酶活性持续增强，细胞表型转化，促进细胞增殖和信号的传导，在调节肿瘤细胞的生长、损伤、修复、新生血管生成、侵袭和转移中具有重要作用 [<xref ref-type="bibr" rid="hanspub.40035-ref17">17</xref>]。其过度表达与许多恶性肿瘤的发生、进展相关，包括非小细胞肺癌、乳腺癌、结直肠癌、胰腺癌等。抗EGFR的单克隆抗体主要有西妥昔单抗与帕尼单抗，通过利用KRAS基因检测，KRAS野生型的病人能从这两者靶向药物中获益更多。</p><sec id="s6_2_1"><title>2.2.1. 西妥昔单抗</title><p>西妥昔单抗(Cetuximab)是首个获批用于结直肠癌的重组人鼠嵌合型IgG1的抗EGFR单克隆抗体。它对EGFR的胞外结构域具有高亲和力，它与EGFR的结合阻断了受体相关激酶(MAPK和PI3K/Akt)的磷酸化和激活 [<xref ref-type="bibr" rid="hanspub.40035-ref18">18</xref>]。由于竞争性的与EGFR的细胞外结构域结合，抑制下游信号传递，从而使得肿瘤周期停滞，使肿瘤细胞发生凋亡，抑制肿瘤新生血管生成、肿瘤转移，并使EGFR的内吞导致受体数量下调，抗体依赖细胞的细胞毒性和放射或化疗敏感性增强 [<xref ref-type="bibr" rid="hanspub.40035-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40035-ref19">19</xref>]。经多项研究表明，西妥昔单抗在胃癌、头颈部鳞状细胞癌、膀胱癌、非小细胞肺癌等多种实体瘤的治疗中发挥重要的作用，并与其预后性有关。被批准用于一线治疗联合化疗或作为单一药物治疗失败或不耐受化疗的患者EGFR表达，KRAS野生型转移性结直肠癌，最常见的不良反应是皮肤毒性 [<xref ref-type="bibr" rid="hanspub.40035-ref19">19</xref>]。</p><p>一项研究表明 [<xref ref-type="bibr" rid="hanspub.40035-ref20">20</xref>]，在野生型K-ras肿瘤患者中，西妥昔单抗治疗与单纯支持治疗相比，总体生存率显著提高(中位数9.5个月比4.8个月)和无进展生存率(中位数3.7个月比1.9个月；而在突变的K-ras肿瘤患者中，接受西妥昔单抗治疗的患者与单独接受支持性化疗的患者在总体生存率无统计学意义。由此可得出携带突变K-ras的结直肠肿瘤患者不受益于西妥昔单抗，而携带野生型K-ras的肿瘤患者确实受益于西妥昔单抗，RAS基因(NRAS和KRAS)的缺失决定了西妥昔单抗治疗的效果。K-ras基因突变状态对单纯支持治疗的患者的生存无影响。</p><p>CRYSTAL研究 [<xref ref-type="bibr" rid="hanspub.40035-ref21">21</xref>] 表明西妥昔单抗联合伊立替康能够显著提高PFS和ORR，且耐受性较好，同时EPIC研究 [<xref ref-type="bibr" rid="hanspub.40035-ref22">22</xref>] 显示，西妥昔单抗联合伊立替康显著改善了PFS和RR，作为二线治疗，可用于K-ras基因野生型晚期结直肠癌患者，是基于奥沙利铂或伊立替康等一线治疗失败的基础上。值得注意的是，肿瘤在结直肠癌发生的位置也会对预后有影响，相关研究提示左侧RAS野生型mCRC(LC)患者与右侧mCRC(RC)相比，EGFR抑制剂的PFS、OS和应答率(RR)更好。右侧肿瘤通常激活RAS和BRAF突变，这导致西妥昔单抗的预后和治疗更差。左侧肿瘤似乎与EGFR的激活更密切相关。因此，左侧RAS野生型mCRC患者应优先使用抗EGFR抗体治疗 [<xref ref-type="bibr" rid="hanspub.40035-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.40035-ref24">24</xref>]。</p></sec><sec id="s6_2_2"><title>2.2.2. 帕尼单抗</title><p>帕尼单抗(Panitumumab)是第一个具有完全人源化特性的IgG2单克隆抗体，可与结直肠肿瘤细胞的EGFR特异性结合，无论正常或肿瘤细胞，均对EGFR有着高度亲和力，是一种EGFR配体的特异性的竞争性抑制剂 [<xref ref-type="bibr" rid="hanspub.40035-ref25">25</xref>]。2006年9月被批准用于标准化疗方案治疗失败的转移性结直肠癌患者可作为单药三线治疗。帕尼单抗联合化疗较单药化疗相比，能显著提高KRAS基因野生型mCRC的客观缓解率和疾病控制率，延长PFS [<xref ref-type="bibr" rid="hanspub.40035-ref26">26</xref>]。</p><p>Douillard [<xref ref-type="bibr" rid="hanspub.40035-ref27">27</xref>] 等在512例无RAS突变的结直肠癌患者中进行分析，帕尼单抗联合FOLFOX4的无进展生存期为10.1个月，而单纯FOLFOX4化疗组的无进展生存期为7.9个月。帕尼单抗组总生存期为26.0个月，而对照组仅为20.2个月。研究表明帕尼单抗联合治疗使患者的PFS、OS得到了明显改善。抗EGFR单克隆抗体可明显改善KRAS基因野生型mCRC患者的OS，但相对于KRAS基因突变型mCRC患者使用抗EGFR单抗治疗无明显改善，推荐mCRC患者在使用帕尼单抗等靶向药物前需进行KRAS基因型检测，从而确保化疗的有效性 [<xref ref-type="bibr" rid="hanspub.40035-ref28">28</xref>]。</p></sec></sec><sec id="s6_3"><title>2.3. 多靶点磷酸激酶抑制剂类药物或酪氨酸激酶受体的小分子抑制剂(TKI)</title><sec id="s6_3_1"><title>2.3.1. 瑞戈非尼</title><p>瑞戈非尼(Regorafenib)是一种新型的口服小分子多靶点磷酸激酶抑制剂，可阻断多种蛋白激酶的活性，包括参与调节肿瘤血管生成的激酶VEGFR1、VEGFR2、VEGFR3、TIE2、肿瘤发生(KIT、RET、RAF1、BRAF和BRAFV600E)以及肿瘤微环境(PDGFR和FGFR)，导致肿瘤的生成、新生血管发生以及肿瘤微环境信号传导通路的维持等受到抑制，在一系列临床试验中，瑞戈非尼显示了抗肿瘤活性，包括在结直肠癌患者中 [<xref ref-type="bibr" rid="hanspub.40035-ref29">29</xref>]。</p><p>CORRECT [<xref ref-type="bibr" rid="hanspub.40035-ref29">29</xref>] 研究是一项随机双盲Ⅲ期临床研究，该研究在16个国家的114个中心进行了试验。将760名患者随机分配接受瑞戈非尼(n = 505)和对照组(n = 255)，瑞戈非尼组中位总生存期为6.4个月，安慰剂组为5.0个月(危险比0.77，单侧p = 0.0052)。与瑞戈非尼有关的三级或以上最常见的不良事件是手足皮肤反应(17%)、疲劳(10%)、腹泻(7%)、高血压(7%)和皮疹或脱屑(6%)。从该研究可得出，瑞戈非尼是一种可延长结直肠癌患者生存期的小分子多激酶抑制剂，其安全性及疗效较好。CONCUR [<xref ref-type="bibr" rid="hanspub.40035-ref30">30</xref>] 研究也为瑞戈非尼在结直肠癌患者中的安全性和有效性提供另一证据。</p></sec><sec id="s6_3_2"><title>2.3.2. 呋喹替尼</title><p>呋喹替尼(Fruquintinib)是一种新型的口服小分子化合物，选择性地抑制血管内皮生长因子受体(VEGFR1-3)，对多种人类肿瘤异种移植物有较强的抑制作用，在晚期实体肿瘤患者中显示出可接受的安全性和抗肿瘤活性的初步证据 [<xref ref-type="bibr" rid="hanspub.40035-ref31">31</xref>]。2018年9月，中国国家医药产品管理局批准用于转移性结直肠癌的患者，这些患者至少先前在两种的全身抗肿瘤治疗中失败，包括奥沙利铂或伊立替康联合亚叶酸钙。在中国，Fruquintinib正在进行第三阶段的临床开发，用于治疗晚期NSCLC(FALUCA试验；NCT02691299)和晚期胃癌(FRUTIGA试验；NCT03223376) [<xref ref-type="bibr" rid="hanspub.40035-ref32">32</xref>]。</p></sec><sec id="s6_3_3"><title>2.3.3. 法米替尼</title><p>法米替尼(Famitinib)是一种新型、有效的受体酪氨酸激酶抑制剂，可作用于干细胞生长因子受体(c-kit)、血管内皮生长因子受体2和3(VEGFR-2和-3)、血小板衍生生长因子受体、酪氨酸蛋白激酶受体等，一项研究表明，法米替尼具有良好的耐受性，具有广泛的抗肿瘤活性。在二线治疗后的晚期结直肠癌患者中进行了随机、双盲、多中心的II期临床试验 [<xref ref-type="bibr" rid="hanspub.40035-ref33">33</xref>]，该研究主要终点为PFS、OS，154名患者以2：1的比例接受法米替尼(n = 99)或安慰剂(n = 55)，法米替尼组PFS较安慰剂组明显延长，由1.5个月延长至2.8个月(危险比 = 0.60，P = 0.004)；法米替尼组和安慰剂组疾病控制率(Disease control rate, DCR)分别为59.8%和31.4% (P = 0.002)，ORR分别为2.2%和0.0% (P = 0.540)；最常见的3~4级不良事件是高血压(11.1%)、手足综合征(10.1%)、血小板减少(10.1%)和中性粒细胞减少(9.1%)；法米替尼组11例(11.1%)和安慰剂组5例(9.1%)发生严重不良事件(P = 0.788)，而法米替尼和安慰剂组的中位OS为7.4和7.2个月(P = 0.657)，差异无统计学意义 [<xref ref-type="bibr" rid="hanspub.40035-ref33">33</xref>]。该研究结果表明，法米替尼可改善了晚期转移性结直肠癌患者的PFS，但对OS无明显影响，具有良好的疗效和安全性。关于法米替尼的III期临床试验正在进行中，旨在观察法米替尼能否在至少二线治疗后的提高晚期结直肠癌患者的OS。</p></sec><sec id="s6_3_4"><title>2.3.4. 安罗替尼</title><p>安罗替尼(Anlotinib)作为一种新型小分子多靶点酪氨酸激酶抑制剂，主要通过作用于血管内皮生长因子受体、血小板衍生生长因子受体(PDGFR)、成纤维生长因子受体(FGFR)、c-Kit、Ret等多个靶点，发挥抑制肿瘤生长与转移及抗肿瘤血管的作用。目前临床研究结果在几种类型的实体肿瘤中观察到了初步的疗效，包括非小细胞肺癌、结直肠癌、肾透明细胞癌、甲状腺髓样癌和软组织肉瘤等。已成功获批成为非小细胞肺癌、晚期小细胞肺癌、软组织肉瘤的靶向药 [<xref ref-type="bibr" rid="hanspub.40035-ref34">34</xref>]。相关临床试验正在进行中，为了评估安罗替尼对于晚期标准化疗后再复发的结直肠癌患者的生存获益和安全性 [<xref ref-type="bibr" rid="hanspub.40035-ref35">35</xref>]。</p></sec><sec id="s6_3_5"><title>2.3.5. 阿帕替尼</title><p>阿帕替尼(Apatinib)是一种国产小分子VEGFR-2酪氨酸激酶抑制剂。它能有效抑制肿瘤血管生成，从而控制疾病的发展，延长中位生存期 [<xref ref-type="bibr" rid="hanspub.40035-ref36">36</xref>]。阿帕替尼的II期和III期临床试验证实，它能显著延长晚期胃癌患者的PFS和OS，批准用于进展期胃癌 [<xref ref-type="bibr" rid="hanspub.40035-ref37">37</xref>]。而一项阿帕替尼治疗难治性、转移性结直肠癌的临床II期试验研究中 [<xref ref-type="bibr" rid="hanspub.40035-ref38">38</xref>]，纳入26例经标准方案治疗后出现进展的结直肠癌患者中位PFS为3.9个月，中位OS为7.9个月；PS 0~1分的患者PFS阿帕替尼组比PS 2分的患者长(4.17个月比1.93个月)。无肝转移患者的PFS也比有肝转移的患者长(5.87个月比3.33个月)。常见的不良反应主要为高血压(79.62%)手足综合征(11.54%)、蛋白尿(73.08%)、腹泻(23.08%)。由此可得出，阿帕替尼单药治疗难治性结直肠癌患者，特别是PS 0-1分或无肝转移患者，疗效显著。</p></sec><sec id="s6_3_6"><title>2.3.6. 吉非替尼</title><p>吉非替尼(Gefitnib)作为EGFR酪氨酸激酶的选择性抑制剂，在多种肿瘤中都有EGFR的过度表达，已被用于治疗结直肠癌和其他类型的癌症，无论是作为单药治疗还是与其他药物联合，但在结直肠癌中的作用不如其他类型的癌症有效，比如NSCLC [<xref ref-type="bibr" rid="hanspub.40035-ref39">39</xref>]。</p></sec></sec></sec><sec id="s7"><title>3. 小结</title><p>靶向药物的出现使结直肠癌的治疗进入到崭新阶段，而对靶向药物分子作用机制的深入研究又推进了个体化治疗进程。目前有很多制药公司也正在对其分子靶向进行大量的开发投资。虽然结直肠癌在治疗方法上已经取得了很大的改进和创新，但是化疗仍然是治疗的基础。在未来会以精准化治疗为主要目标，通过基因组与转录组等技术，寻找更精确的生物标志物和治疗靶点，且结合具体患者的癌基因谱，并通过大数据的分析，根据临床规范化指南，遵守循证医学证据，这才能对恶性肿瘤的精准打击最大化，使临床患者受益。大量靶向药物的出现，使得如何选择成为关键，而靶向治疗在维持治疗中如何选择化疗方案配伍能克服耐药也是临床医生需要解决的问题。新的靶向药物及探索新的治疗模式是未来肿瘤治疗的重点研究方向，寻找新的、特异性强的、对机体正常细胞影响小且毒性低的药物是近年来研究的热点。</p></sec><sec id="s8"><title>文章引用</title><p>严双丽,张荣生,王剑华. 结直肠癌靶向药物治疗的应用与进展Application and Progress of Targeted Drug Therapy for Colorectal Cancer[J]. 世界肿瘤研究, 2021, 11(01): 24-31. https://doi.org/10.12677/WJCR.2021.111004</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40035-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.40035-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Francipane, M.G. and Lagasse, E. (2014) mTOR Pathway in Colorectal Cancer: An Update. Oncotarget, 5, 49-66.  
https://doi.org/10.18632/oncotarget.1548</mixed-citation></ref><ref id="hanspub.40035-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ramjiawan, R.R., Griffioen, A.W. and Duda, D.G. (2017) Anti-Angiogenesis for Cancer Revisited: Is There a Role for Combinations with Immunotherapy? Angiogenesis, 20, 185-204. https://doi.org/10.1007/s10456-017-9552-y</mixed-citation></ref><ref id="hanspub.40035-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Baluk, P., Hashizume, H. and McDonald, D.M. (2005) Cellular Abnormalities of Blood Vessels as Targets in Cancer. Current Opinion in Genetics and Development, 15, 102-111. https://doi.org/10.1016/j.gde.2004.12.005</mixed-citation></ref><ref id="hanspub.40035-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1</mixed-citation></ref><ref id="hanspub.40035-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wildiers, H., Guetens, G., De Boeck, G., et al. (2003) Effect of Antivascular Endothelial Growth Factor Treatment on the Intratumoral Uptake of CPT-11. British Journal of Cancer, 88, 1979-1986. https://doi.org/10.1038/sj.bjc.6601005</mixed-citation></ref><ref id="hanspub.40035-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England Journal of Medicine, 350, 2335-2342.  
https://doi.org/10.1056/NEJMoa032691</mixed-citation></ref><ref id="hanspub.40035-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, M.H., Gootenberg, J., Keegan, P. and Pazdur, R. (2007) FDA Drug Approval Summary: Bevacizumab plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer. Oncologist, 12, 356-361.  
https://doi.org/10.1634/theoncologist.12-3-356</mixed-citation></ref><ref id="hanspub.40035-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Spratlin, J.L., Cohen, R.B., Eadens, M., et al. (2010) Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology, 28, 780-787. https://doi.org/10.1200/JCO.2009.23.7537</mixed-citation></ref><ref id="hanspub.40035-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Reck, M., Garon, E.B., Paz-Ares, L., et al. (2018) Randomized, Double-Blind Phase Ib/III Study of Erlotinib with Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 19, 213-220. https://doi.org/10.1016/j.cllc.2017.11.003</mixed-citation></ref><ref id="hanspub.40035-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Verdaguer, H., Tabernero, J. and Macarulla, T. (2016) Ramucirumab in Metastatic Colorectal Cancer: Evidence to Date and Place in Therapy. Therapeutic Advances in Medical Oncology, 8, 230-242.  
https://doi.org/10.1177/1758834016635888</mixed-citation></ref><ref id="hanspub.40035-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Carbonero, R., Rivera, F., Maurel, J., et al. (2014) An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined with mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer. Oncologist, 19, 350-351. https://doi.org/10.1634/theoncologist.2014-0028</mixed-citation></ref><ref id="hanspub.40035-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cai, S. and Bressler, N.M. (2017) Aflibercept, Bevacizumab or Ranibizumab for Diabetic Macular Oedema: Recent Clinically Relevant Findings from DRCR.net Protocol T. Current Opinion in Ophthalmology, 28, 636-643.  
https://doi.org/10.1097/ICU.0000000000000424</mixed-citation></ref><ref id="hanspub.40035-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Van Cutsem, E., Tabernero, J., Lakomy, R., et al. (2012) Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen. Journal of Clinical Oncology, 30, 3499-3506.  
https://doi.org/10.1200/JCO.2012.42.8201</mixed-citation></ref><ref id="hanspub.40035-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Mody, K., Baldeo, C. and Bekaii-Saab, T. (2018) Antiangiogenic Therapy in Colorectal Cancer. The Cancer Journal, 24, 165-170. https://doi.org/10.1097/PPO.0000000000000328</mixed-citation></ref><ref id="hanspub.40035-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gao, M., Liang, X.J., Zhang, Z.S., et al. (2013) Relationship between Expression of EGFR in Gastric Cancer Tissue and Clinicopathological Features. Asian Pacific Journal of Tropical Medicine, 6, 260-264.  
https://doi.org/10.1016/S1995-7645(13)60054-1</mixed-citation></ref><ref id="hanspub.40035-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Akhtar, S., Al-Zaid, B., El-Hashim, A.Z., et al. (2015) Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling in Vitro and in Vivo. PLoS ONE, 10, e0132215. https://doi.org/10.1371/journal.pone.0132215</mixed-citation></ref><ref id="hanspub.40035-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fornasier, G., Francescon, S. and Baldo, P. (2018) An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Advances in Therapy, 35, 1497-1509. https://doi.org/10.1007/s12325-018-0791-0</mixed-citation></ref><ref id="hanspub.40035-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Park, T., Choi, C.J., Choi, Y. and Suh, D.C. (2016) Cost-Effectiveness of Cetuximab for Colorectal Cancer. Expert Review of Pharmacoeconomics &amp; Outcomes Research, 16, 667-677. https://doi.org/10.1080/14737167.2016.1245618</mixed-citation></ref><ref id="hanspub.40035-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine, 359, 1757-1765.  
https://doi.org/10.1056/NEJMoa0804385</mixed-citation></ref><ref id="hanspub.40035-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Van Cutsem, E., Bodoky, G., Kyung Roh, J., et al. (2007) 3001O-RAL Crystal, a Randomized Phase III Trial of Cetuximab plus FOLFIRI vs. FOLFIRI in First-Line Metastatic Colorectal Cancer (mCRC). European Journal of Cancer Supplements, 5, 235. https://doi.org/10.1016/S1359-6349(07)70929-1</mixed-citation></ref><ref id="hanspub.40035-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sobrero, A.F., Maurel, J., Fehrenbacher, L., et al. (2008) EPIC: Phase III Trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26, 2311-2319. https://doi.org/10.1200/JCO.2007.13.1193</mixed-citation></ref><ref id="hanspub.40035-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Holch, J.W., Ricard, I., Stintzing, S., et al. (2017) The Relevance of Primary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. European Journal of Cancer, 70, 87-98.  
https://doi.org/10.1016/j.ejca.2016.10.007</mixed-citation></ref><ref id="hanspub.40035-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tejpar, S., Stintzing, S., Ciardiello, F., et al. (2017) Prognostic and Predictive Relevance of Primary Tumor Location in Patients with RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncology, 3, 194-201. https://doi.org/10.1001/jamaoncol.2016.3797</mixed-citation></ref><ref id="hanspub.40035-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Price, T.J., Peeters, M., Kim, T.W., et al. (2014) Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study. The Lancet Oncology, 15, 569-579.  
https://doi.org/10.1016/S1470-2045(14)70118-4</mixed-citation></ref><ref id="hanspub.40035-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Modest, D.P., Martens, U.M., Riera-Knorrenschild, J., et al. (2019) FOLFOXIRI plus Panitumumab as First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 37, 3401-3411. https://doi.org/10.1200/JCO.19.01340</mixed-citation></ref><ref id="hanspub.40035-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Douillard, J.Y., Oliner, K.S., Siena, S., et al. (2013) Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. The New England Journal of Medicine, 369, 1023-1034. https://doi.org/10.1056/NEJMoa1305275</mixed-citation></ref><ref id="hanspub.40035-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Modest, D.P., Rivera, F., Bachet, J.B., et al. (2019) Panitumumab-Based Maintenance after Oxaliplatin Discontinuation in Metastatic Colorectal Cancer: A Retrospective Analysis of Two Randomised Trials. International Journal of Cancer, 145, 576-585. https://doi.org/10.1002/ijc.32110</mixed-citation></ref><ref id="hanspub.40035-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Grothey, A., Van Cutsem, E., Sobrero, A., et al. (2013) Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 303-312. https://doi.org/10.1016/S0140-6736(12)61900-X</mixed-citation></ref><ref id="hanspub.40035-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Dhillon, S. (2018) Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs, 78, 1133-1144.  
https://doi.org/10.1007/s40265-018-0938-y</mixed-citation></ref><ref id="hanspub.40035-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Cao, J., Zhang, J., Peng, W., et al. (2016) A Phase I Study of Safety and Pharmacokinetics of Fruquintinib, a Novel Selective Inhibitor of Vascular Endothelial Growth Factor Receptor-1, -2, and -3 Tyrosine Kinases in Chinese Patients with Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology, 78, 259-269.  
https://doi.org/10.1007/s00280-016-3069-8</mixed-citation></ref><ref id="hanspub.40035-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Shirley, M. (2018) Fruquintinib: First Global Approval. Drugs, 78, 1757-1761.  
https://doi.org/10.1007/s40265-018-0998-z</mixed-citation></ref><ref id="hanspub.40035-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Xu, R.H., Shen, L., Wang, K.M., et al. (2017) Famitinib versus Placebo in the Treatment of Refractory Metastatic Colorectal Cancer: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase II Clinical Trial. Chinese Journal of Cancer, 36, 97. https://doi.org/10.1186/s40880-017-0263-y</mixed-citation></ref><ref id="hanspub.40035-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Y., Niu, W., Du, F., et al. (2016) Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients with Advanced Refractory Solid Tumors. Journal of Hematology &amp; Oncology, 9, 105. https://doi.org/10.1186/s13045-016-0332-8</mixed-citation></ref><ref id="hanspub.40035-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, A.P., Bai, Y., Song, Y., et al. (2019) Anlotinib versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. Oncologist, 24, e702-e708.  
https://doi.org/10.1634/theoncologist.2018-0839</mixed-citation></ref><ref id="hanspub.40035-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y., Zhou, P., Lin, Y., et al. (2019) Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib. Journal of Biomedical Nanotechnology, 15, 1256-1266. https://doi.org/10.1166/jbn.2019.2770</mixed-citation></ref><ref id="hanspub.40035-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Geng, R., Song, L., Li, J. and Zhao, L. (2018) The Safety of Apatinib for the Treatment of Gastric Cancer. Expert Opinion on Drug Safety, 17, 1145-1150. https://doi.org/10.1080/14740338.2018.1535592</mixed-citation></ref><ref id="hanspub.40035-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Qiu, T., Zhu, Y., et al. (2019) A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. Oncologist, 24, 883-e407. https://doi.org/10.1634/theoncologist.2019-0164</mixed-citation></ref><ref id="hanspub.40035-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.C., Chin, Y.T., Nana, A.W., et al. (2018) Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation. Hormones and Cancer, 9, 420-432. https://doi.org/10.1007/s12672-018-0341-x</mixed-citation></ref></ref-list></back></article>